The Biotechnology Industry Organization (BIO) announced the companies confirmed to present at the 2013 BIO International Convention.
The Biotechnology Industry Organization (BIO) announced the companies confirmed to present at the 2013 BIO International Convention in sessions designed to increase visibility, attract more partners, and pitch their business objectives to a global audience.
The BIO International Convention, scheduled for April 22-25 at McCormick Place in Chicago, will highlight the trends and opportunities for executives, investors, scientists, policy leaders, and media in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues, and food and agriculture. The event is hosted by the Biotechnology Industry Organization (BIO).
The BIO Business Forum will host partnering meetings, workshops and a full program of sessions geared toward life science executives. The Business Development educational track will feature education programming discussing partnering, emerging markets, big pharma, and deal making.
“Now in its twelfth year, the industry’s largest partnering event is looking to host a record breaking 25,000+ partnering meetings this year via the One-on-One Partnering System in the BIO Business Forum and BIO Exhibition,” said BIO’s CEO and President Jim Greenwood. “The One-on-One Partnering System facilitates an unparalleled opportunity for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather in one place, meet one-on-one, and discuss business opportunities.”
Other events include Exhibitor Booth Partnering, which allows qualified exhibitors to schedule meetings in their personal exhibitor booths; and the Rare Disease Partnering Summit, which features presentations from pediatric research institutions. Five of these pediatric institutions will present their translational research projects and partnering opportunities focused on rare diseases, April 24 from 2 – 5 p.m.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.